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ABSTRACT
The conditions and outcomes of Japanese patients with prostate cancer who developed PSA failure after radical
prostatectomy (RP), and who were treated via salvage radiotherapy (S-RT), were surveyed. Clinical data on S-RT
were gathered in questionnaires completed by facilities participating in the Japanese Radiation Oncology Study
Group. S-RT was deﬁned as external-beam radiotherapy delivered to the prostate beds of patients with prostate
cancer who had eventually developed PSA failure, although their PSA values had at one stage attained levels
<0.2 ng/ml following RP. Hormonal therapy was combined with S-RT in ∼40% of cases. Outcomes were evalu-
ated in 186 cases treated via S-RT alone. The nadir PSA level after RP, and the level upon initiation of S-RT, were
0.0135 ng/ml and 0.292 ng/ml, respectively. The median period between RP and S-RT was 18.6 months. The
median follow-up period was 58 months. The 5-year PSA recurrence–free survival (PRFS) and clinical failure–free
survival (CFFS) rates were 50.1% (95% CI: 42.8–57.9%) and 90.1% (95% CI: 86.4–95.7%), respectively. PRFS
was signiﬁcantly superior in patients with PSA values ≤0.3 ng/ml upon initiation of S-RT than in those with PSA
values >0.3 ng/ml (57.5% vs 40.5%, P = 0.027). In Japan, hormonal therapy is combined with S-RT in ∼40% of
cases. The 5-year PRFS and CFFS rates of cases treated via S-RT alone were 50.1% and 90.1%, respectively. A PSA
value of 0.3 ng/ml served as a signiﬁcant cut-off for prediction of PRFS.
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INTRODUCTION
Radical prostatectomy (RP) is one of the principal treatment modal-
ities for localized prostate cancer. However, about 20–30% of patients
with localized disease treated via RP eventually experience recurrences
[1]. Of such cases, some patients exhibit clinical recurrence, including
lymph node and bone metastases. However, most recurrences are pros-
tate-speciﬁc antigen (PSA) recurrences, in which continuous rises in
PSA levels are observed, without any evidence of clinical failure, after a
very low PSA nadir value has been attained after RP. It has been
reported that 34% of PSA-recurrent cases develop metastatic disease at
a median time of 8 years after such PSA elevations, and die at a median
time of 5 years from development of metastatic disease [1].
In patients exhibiting PSA recurrence, salvage radiotherapy
(S-RT) is considered to be the only curative treatment. Therefore,
S-RT has been widely used to treat those who have developed PSA
recurrence after RP, although the impact thereof on survival remains
under investigation by the Japan Clinical Oncology Group (JCOG)
(the JCOG 0401 study [2]). The American Society for Radiation
Oncology (ASTRO)/American Urological Association (AUA) guide-
lines strongly recommend that S-RT should be offered to patients
exhibiting PSA or local recurrence after RP, if there is no evidence of
distant metastatic disease [3]. However, no nationwide data on the
outcomes of S-RT in Japan are available. Therefore, we conducted
the present study to determine the actual conditions and outcomes of
patients treated with S-RT upon the development of PSA recurrence
after RP in Japan.
METHODS
A registry was established by facilities participating in the Japanese Radi-
ation Oncology Study Group ( JROSG). Eligible cases were patients
with localized prostate cancer who were treated via RP prior to 2005
and who received S-RT between January 2005 and December 2007
because of PSA failure. The cut-off PSA value for PSA failure was
deﬁned as 0.2 ng/ml based on the Guidelines for Clinical Practices of
Prostate Cancer edited by the Japanese Urorogical Association [4], and
the ASTRO/AUA guidelines [3]. S-RT featured external-beam radio-
therapy delivered to the prostate beds of patients with prostate cancer
who had eventually developed PSA failure after RP, although their PSA
levels had once dropped below 0.2 ng/ml at some point after RP. There-
fore, patients with minimum PSA values after RP (the PSA nadirs) of
0.2 ng/ml or higher were excluded from the present study. In addition,
the interval between RP and S-RT was essentially required to be 6
months or longer. Patients in whom EBRT was delivered to the prostate
bed earlier than 3 months after RP were considered to have received adju-
vant radiotherapy, and their data were reported separately [5]. Because
pre-operative and operative factors have been well studied [6, 7], this
survey focused on the post-operative factors relating to S-RT in order
to maximize the reliability of data from busy JROSG facilities.
PSA recurrence–free survival (PRFS) and clinical failure–free sur-
vival (CFFS) rates were calculated via the Kaplan–Meier method, com-
mencing on the dates of initiation of S-RT. The statistical signiﬁcances
of observed differences in survival curves were estimated using the log-
rank test. PSA recurrence developing after S-RT was deﬁned as follows:
The PSA level became re-elevated to 0.2 ng/ml or higher in patients in
whom the PSA level had once dropped below 0.2 ng/ml after S-RT, or
was 0.2 ng/ml or higher on the date of the ﬁrst measurement of PSA
level after S-RT if the PSA level had never fallen below 0.2 ng/ml.
Cox’s proportional hazard modeling was used to explore the predictive
signiﬁcance of factors associated with PRFS. The grading of each
adverse event was based on the Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0; JCOG [8]. The Mann–
Whitney U-test was used to compare the incidences of adverse events
among patients treated with different radiation techniques or radiation
doses. Statistical analyses were performed with the aid of GraphPad
Prism 5.04 (GraphPad Software Inc., La Jolla, CA, USA) and StatView
(ver. 5.0; SAS Institute Inc., Cary, NC, USA) software packages.
The present study was designed and conducted by the Urologic
Oncology Subgroup of the JROSG. The study was also approved by
the Institutional Review Boards of Kyoto University (Approval No.:
E-1007) and Jikei University, and conducted in accordance with the
dictates of the Helsinki Declaration.
RESULTS
Overview of the cases
Data on 371 cases treated in 38 facilities were sent to the JROSG
registry between October 2011 and January 2012. Hormonal therapy
was combined with S-RT in 151 patients (40.7% of all cases). In
three cases, chemotherapy was added before or after S-RT. The rest
of the cases were treated via S-RT alone. However, prognostic infor-
mation was insufﬁcient in 28 cases, and the PSA nadir value was
higher than 0.2 ng/ml in a further 3 cases. Therefore, PRFS and
CFFS were evaluated for the remaining 186 cases who met the cri-
teria for S-RT and who were treated via S-RT alone. PSA doubling
time was not included in the current analyses, because it was not
reported in many cases.
Characteristics of cases treated via S-RT alone
The characteristics of the 186 cases treated via S-RT alone are sum-
marized in Table 1. The median patient age was 67 years. The nadir
Table 1. Characteristics of the S-RT–alone cases
Age (years) Range: 49–82
Median: 67
Mean: 66
PSA nadir after RP (ng/ml) Range: <0.0–0.191
Median: 0.0135
Mean: 0.032
PSA at initiation of S-RT (ng/ml) Range: 0.02–3.63
Median: 0.292
Mean: 0.402





PSA = prostate-speciﬁc antigen, RP = radical prostatectomy, S-RT = salvage
radiotherapy.
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PSA level after RP and the PSA level at initiation of S-RT were
0.0135 ng/ml and 0.292 ng/ml, respectively. The median period
between RP and S-RT was 18.6 (range: 3.8–80.5) months. In seven
cases, S-RT was commenced between 3 and 6 months after RP (3.8–
5.2 months).
Details of S-RT
Of the 186 cases, computed tomography-based simulations were per-
formed on 155, whereas X-ray simulations were performed on 31.
The prostate bed, small pelvis and entire pelvis were irradiated in 176,
8 and 2 cases, respectively. Three-dimensional conformal radiation
therapy (3D-CRT) with ﬁve portals or more, the four-ﬁeld box tech-
nique, and an anterior–posterior opposing ﬁeld, were used in 88, 96
and 2 cases, respectively. The X-ray energies were as follows: 6 MV in
6, 10 MV in 144, and >10 MV in 34 cases, respectively. The pre-
scribed doses were >70 Gy, >65 Gy to ≤70 Gy, >60 Gy to ≤65 Gy,
and ≤60 Gy in 6, 70, 105 and 5 patients, respectively. The cone-
down technique was used in 71 cases, with boost plans applied after a
median dose of 45.8 Gy (range: 30–60 Gy) had been delivered. A
summary of the S-RTs applied is shown in Table 2.
Oncological outcomes of S-RT
The median follow-up period was 58 months (range: 3–83 months).
The 5-year PRFS and CFFS were 50.1% (95% CI: 42.8–57.9%) and
90.1% (95% CI: 86.4–95.7%), respectively (Figs 1 and 2). Of the
PSA level at initiation of S-RT (the pre-S-RT PSA), the PSA nadir
attained after RP, the period between RP and S-RT, radiation dose,
and age, only the pre-S-RT PSA level signiﬁcantly predicted PRFS
upon both univariate and multivariate analyses (Table 3). The PRFS
was signiﬁcantly longer in patients with PSA values ≤0.3 ng/ml at ini-
tiation of S-RT than in those with PSA levels >0.3 ng/ml (57.5% vs
40.5%, P = 0.027) (Fig. 3). With other PSA cut-off values at S-RT,
the differences were not statistically signiﬁcant (P = 0.44, 0.051 and
0.21 for 0.2, 0.4 and 0.5 ng/ml, respectively).
Adverse events
The crude incidences of Grade 1, 2 and 3 acute adverse events were
51.1%, 7.0% and 0.5% for genitourinary (GU) events, and 36.6%,
22.0% and 0% for gastrointestinal (GU) events, respectively. No
Grade 4 or higher acute adverse event was observed. The acute toxici-
ties are listed in Table 4. Reported late adverse events are summarized
in Table 5. The crude incidences of Grade 1, 2 and 3 late adverse
events were 29.6%, 13.4% and 2.7% for GU events, and 15.6%, 4.3%
and 0% for GI events, respectively. No Grade 4 or higher late toxicity
was observed in either the acute or late phase.
Incidences of acute GU, acute GI and late GI adverse events were
signiﬁcantly lower in patients treated with ≥5-ﬁeld technique
















>65 Gy to ≤70 Gy 70
>60 Gy to≤65 Gy 105
≤ 60 Gy 5
CT = computed tomography.
Fig 1. Kaplan–Meier curve with 95% conﬁdence interval
of PSA recurrence–free survival.
Fig 2. Kaplan–Meier curve with 95% conﬁdence interval
for clinical failure–free survival.
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compared with those who irradiated with the 4-ﬁeld technique
(P value: <0.0001, 0.0063 and 0.0024, respectively) (Tables 6 and 7).
On the other hand, incidences of late GU events were signiﬁcantly
higher in patients who received higher radiation doses (P = 0.028)
(Table 7).
DISCUSSION
S-RT is recognized as the sole approach affording an opportunity of a
cure to patients with localized prostate cancer who develop PSA
recurrence after RP [6]. The principal purpose of S-RT is to reduce
the PSA level to the limit of detection, and maintain PSA recurrence-
free status. According to a recent publication, the PSA recurrence-free
rates were generally 30–60% 3–6 years after S-RT [6]. King per-
formed a systematic review of S-RT based on the data of 41 reports,
including 5597 cases, and the average 5-year PSA control rate was
46.2% [9]. In Japan, Kinoshita reported a 5-year PSA recurrence–free
rate of 42.2% [10]. Therefore, long-term PSA control can generally
be expected in about half of all patients who receive S-RT. The result
of a current surveillance study (5-year PRFS rate = 50.4%) is very
consistent with those of previous reports, and it will be possible
to conclude that long-term PSA control may be expected in about
half of all patients treated with S-RT, in Japan, following PSA failure
after RP.
Various predictors of PRFS have been reported, including the
pathological T-stage at RP, seminal vesicle (SV) invasion, surgical
margin status, Gleason’s score (GS), the period elapsing between RP
and PSA failure, combined hormonal therapy, PSA doubling time,
radiation dose, and PSA level at the time of S-RT initiation (pre-
S-RT PSA) [6]. Generally, higher T-stage, positive SV invasion, a
higher GS, a shorter period between RP and PSA failure, a shorter
PSA doubling time, a lower radiation dose, and a higher pre-S-RT
PSA level, predict poor PRFS. However, considerable among-report
inconsistencies are evident.
Among possible predictors of PRFS, the pre-S-RT PSA level has
consistently been found to be signiﬁcant. King, in a comprehensive
systematic review of S-RT, found that only the pre-S-RT PSA level
(P < 0.001) and the radiation dose (P = 0.052) were independent
signiﬁcant predictors of PRFS [6, 9]. The PFRS fell by an average of
2.6% for each incremental 0.1 ng/ml of PSA level at the time of initi-
ation of S-RT. This study affords Level 2a evidence for initiation of
S-RT at the lowest possible PSA level. The results of our current
study are in line with those of King. In the present study, the 5-year
PRFS rates were 57.5% and 40.5% for patients who received S-RT at
PSA values of 0.3 ng/ml or lower, and those commenced on S-RT at
PSA levels over 0.3 ng/ml, respectively (P = 0.027).
We believe this ﬁnding is very important, because it ﬁnds immedi-
ate application in daily clinical practice. It is not in fact difﬁcult to
commence S-RT in routine practice as early as possible after PSA
failure is observed, to (possibly) improve PRFS. In this sense, the
pre-SRT PSA level is a very practicable predictive factor that can be
used in daily clinical practice. On the other hand, most other possible
predictive factors, including pathological T-stage, SV invasion, surgi-
cal margin status, and GS, are based on pre-operative or operative
data. If a patient develops PSA failure after RP, it is usually difﬁcult to
decide not to offer S-RT to those with unfavorable predictions,
because S-RT is the sole deﬁnitive treatment for cases who develop
PSA recurrence after RP, and not all patients with poor predictors fail
to beneﬁt from S-RT.
Another possible means of improving PRFS after S-RT may be
dose escalation. In the work of King, radiation dose was another inde-
pendent predictor of PRFS [9]. S-RT doses in the range 60–70 Gy
lie in the steep region of the sigmoid dose–response curve; a dose of
70 Gy was associated with 54% PRFS compared with only 34% for
60 Gy. However, no consensus has yet been reached on the optimal
Table 3. Univariate and multivariate analyses of factors predicting PSA failure–free survival upon Cox’s proportional hazard
modeling
Univariate Multivariate
Factor HR 95% CI P HR 95% CI P
Pre-S-RT PSA 1.60 (1.01–2.52) 0.045 1.64 (1.03–2.61) 0.035
PSA nadir after RP 1.61 (0.01–259.95) 0.85 0.375 (0.002–88.09) 0.73
Period between RP and S-RT 1.00 (1.00–1.00) 0.68 1.00 (1.00–1.00) 0.28
Radiation dose (<65 Gy) 1.41 (0.92–2.15) 0.12 1.44 (0.94–2.22) 0.096
Age 1.02 (0.98–1.05) 0.31 1.02 (0.99–1.06) 0.24
PSA = prostate-speciﬁc antigen, S-RT = salvage radiation therapy, RP = radical prostatectomy, HR = hazard ratio, CI = conﬁdence interval.
Fig 3. Kaplan–Meier curves for PSA recurrence–free
survival, according to PSA level at initiation of salvage
radiotherapy (PSA≤ 0.3 ng/ml vs PSA > 0.3 ng/ml).
Salvage radiotherapy after prostatectomy • 753
radiation dose for S-RT. In the present work, the radiation dose did
not predict PRFS. This may be attributable to the fact that most
patients (94%) in our series were treated with doses of 60–70 Gy;
only six cases (3%) received 70 Gy or higher. The impact of dose
escalation during S-RT delivered in Japan should be explored in
future.
Toxicities associated with S-RT were very limited in our series of
patients, in agreement with previously published data [6]. In our
series, no Grade 4 or higher acute or late toxicity (either GU or GI)
was observed. The incidences of Grade 3 toxicities were only 0.5%
and 0% (acute GU and GI toxicities) and 2.7% and 0% (late GU and
GI toxicities), respectively.
Adjuvant radiotherapy (A-RT) is also strongly recommended to
patients with adverse pathological ﬁndings after RP (i.e. SV invasion,
positive surgical margins, and/or extracapsular extensions), based
on three randomized trials, all of which found that A-RT was useful
[3, 11–14]. No completed trial has directly compared S-RT with A-
RT. Although several retrospective comparisons between the two
approaches have been conducted, it is impossible to retrospectively
determine whether either modality is superior to the other. This is
Table 5. Incidences of late adverse events
Incidence (%)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
GU Miction pain 93.0 7.0 0 0 0
toxicity Incontinence 68.8 23.1 7.5 0.5 0
Pollakisuria/
urgency
80.6 17.2 2.2 0 0
Retention/
obstruction
91.4 5.9 1.6 1.1 0
Hematuria 82.3 12.9 3.8 1.1 0
Any GU event 54.3 29.6 13.4 2.7 0
GI Proctitis 90.3 9.1 0.5 0 0
toxicity Rectal bleeding 83.3 15.1 1.6 0 0
Perianal
mucositis
91.4 5.9 2.7 0 0
Any GI event 80.1 15.6 4.3 0 0
GU = genitourinary, GI = gastrointestinal.
Table 4. Incidences of acute adverse events
Incidence (%)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
GU Miction pain 82.3 17.7 0 0 0
toxicity Incontinence 87.6 11.3 1.1 0 0
Pollakisuria/urgency 48.4 45.7 5.9 0 0
Retention/obstruction 91.4 8.1 0 0.5 0
Any GU event 41.4 51.1 7.0 0.5 0
GI Proctitis 70.4 29.0 0.5 0 0
toxicity Rectal bleeding 80.1 15.6 4.3 0 0
Perianal mucositis 58.6 21.5 19.9 0 0
Any GI event 41.4 36.6 22.0 0 0
GU = genitourinary, GI = gastrointestinal.
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because patients who would not have developed recurrences without
further intervention were included in the A-RT group, whereas all
patients receiving S-RT had actually suffered recurrences. Currently,
two prospective randomized trials comparing A-RT with a ‘wait-and-
see’ policy following S-RT initiation at early trigger points (PSA > 0.1
or 0.2 ng/ml) are ongoing [15, 16].
Although S-RT affords an ∼50% chance of further long-term PSA
control in patients who exhibit PSA recurrence after RP, no extra sur-
vival beneﬁt thereof has been proven in comparison with hormonal
therapy (HT) alone. The JCOG 0401 study was designed to answer
this question [2]; however, the study is not yet complete. Even if the
survival outcomes of the S-RT- and HT-alone groups are shown to
be comparable, S-RT would still have the advantage of affording an
HT-free chance in about half of all patients experiencing recurrence.
Therefore, we believe that S-RT will play a useful role in patients who
develop PSA failure after RP.
In conclusion, hormonal therapy is combined with S-RT in ∼40%
of cases in Japan. S-RT is commenced when the PSA level attains
∼0.3 ng/ml (on average). The 5-year PRFS and CFFS rates of cases
treated via S-RT alone were 50.1% and 90.1%, respectively. Inci-
dences of acute GU, acute GI and late GI events were signiﬁcantly
lower in patients treated with 3D-CRT with ﬁve portals or more,
when compared with those treated with the 4-ﬁeld technique. A PSA
value of 0.3 ng/ml was a signiﬁcant cut-off predicting PRFS.
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